Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ITIL-168 |
| Synonyms | |
| Therapy Description |
ITIL-168 is comprised of patient tumor derived tumor-infiltrating lymphocytes, which potentially induce killing of tumor cells (Journal for ImmunoTherapy of Cancer 2021;9; NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ITIL-168 | ITIL 168|ITIL168 | ITIL-168 is comprised of patient tumor derived tumor-infiltrating lymphocytes, which potentially induce killing of tumor cells (Journal for ImmunoTherapy of Cancer 2021;9; NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05050006 | Phase II | ITIL-168 | ITIL-168 in Advanced Melanoma (DELTA-1) | Terminated | USA | GBR | CAN | 0 |